Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028

Foghorn Therapeutics Inc.

Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).
Offering priced at 30% premium to Jan 9, 2026 closing; investors include BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund.
Pro forma cash, cash equivalents and marketable securities of $208.9M (unaudited) as of Jan 13, 2026; cash runway extended into first half of 2028.
FHD-909 (SMARCA2 inhibitor) Phase 1 dose-escalation trial on track; enrollment in NSCLC patients progressing as planned.
Selective CBP degrader on track to be IND-ready in 2026; selective EP300 degrader expected to enter IND-enabling studies in 2026; ARID1B degrader advancing to in vivo PoC in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.